Article PDF first page preview

First page of Predictors of the need for additional postoperative treatment for eosinophilic chronic rhinosinusitis

Introduction. We retrospectively analysed the background and treatment effects of patients who improved with steroid treatment alone and those in whom steroids were ineffective and required dupilumab or revision functional endoscopic sinus surgery (FESS) for postoperative recurrence of eosinophilic chronic rhinosinusitis (ECRS). The objective of this study was to determine the factors influencing the effectiveness of steroid treatment and to evaluate the outcomes of alternative treatments, such as dupilumab or revision FESS. Methods. Between April 2007 and July 2021, 118 adult patients with ECRS who underwent an initial FESS and required additional treatment (corticosteroids, dupilumab, or revision FESS) were included. Responders included 84 patients who required steroid treatment, and non-responders comprised 34 patients who required dupilumab or revision FESS for postoperative recurrence. Patient characteristics (age, sex, bronchial asthma, aspirin intolerance, period from onset to initial FESS), questionnaires (self-administered odour questionnaire and nasal symptoms questionnaire), and results of examinations (JESREC score, peripheral blood eosinophils, non-specific IgE level, mean olfactory detection and recognition thresholds, intravenous olfactory test, and CT score) were compared. Results. The period from onset to initial FESS was significantly longer in non-responders than that in responders (p < 0.001). In both groups, in questionnaires and detection and recognition thresholds in the standard olfactory test, significant improvements were observed after treatment (p < 0.05). However, no significant differences in the questionnaires and examinations were observed between the two groups after treatment. Conclusion. Early therapeutic intervention is important because the period from onset to initial FESS affects the therapeutic effect of steroids on ECRS. Dupilumab or reoperation has been suggested to provide equivalent treatment outcomes even in patients who are resistant to steroids after surgery.

Journal Section:
The Smell and Taste Corner
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025